Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Petru, E; Angleitner-Boubenizek, L; Reinthaller, A; Deibl, M; Zeimet, AG; Volgger, B; Stempfl, A; Marth, C.
Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and -resistant ovarian cancer after previous platinum-taxane therapy: a phase II Austrian AGO study.
Gynecol Oncol. 2006; 102(2):226-229 Doi: 10.1016/j.ygyno.2005.12.017
Web of Science PubMed FullText FullText_MUG Google Scholar

Leading authors Med Uni Graz: Petru Edgar
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: Objectives. Platinum resistance is a significant problem in patients with ovarian cancer. The aim of this phase II study was to define the response rates, the progression-free survival and the toxicity profile of the combination of PEG liposomal doxorubicin (L-DXR) and gemcitabine (GEM). Material and methods. Thirty one patients with histologically confirmed platinum-refractory or -resistant epithelial ovarian cancer were scheduled to receive 6 cycles of L-DXR 30 mg/m(2) on day 1 as well as GEM 650 mg/m(2) on days 1 and 8 every 28 days. Results. The median number of chemotherapy cycles given was 4. The mean dose intensity for L-DXR and GEM on day 1 was 96% and 97%, respectively. The mean dose intensity for GEM on day 8 was 93%. The overall response rate was 33% (10 of 30 evaluable patients; 20% complete responses). The median progression-free survival was 3.8 months, and the median overall survival was 15.8 months, respectively. Toxicity was acceptable. One quarter of patients developed grade 3 or 4 neutropenia, but none developed febrile neutropenia. Palmoplantar erythrodysesthesia (PPE) grades 2 and 3 occurred in 13% and 3% only, respectively, and no grade 4 PPE was observed. Grades 1 to 3 stomatitis was found in 58% of patients (10% grade 3). Conclusion. The combination of L-DXR and GEM is an active and acceptably tolerated option in the treatment of patients with platinum-resistant and -refractory ovarian cancer. Dose reductions seem advisable in the case of >= grade 2 stomatitis and/or PPE grade 2. (c) 2005 Elsevier Inc. All rights reserved.
Find related publications in this database (using NLM MeSH Indexing): Adult -; Aged -; Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Deoxycytidine - administration & dosage Deoxycytidine - adverse effects Deoxycytidine - analogs & derivatives; Disease-Free Survival -; Doxorubicin - administration & dosage Doxorubicin - adverse effects Doxorubicin - analogs & derivatives; Female -; Humans -; Middle Aged -; Neoplasm Recurrence, Local - drug therapy; Ovarian Neoplasms - drug therapy; Polyethylene Glycols - administration & dosage Polyethylene Glycols - adverse effects; Quality of Life -
Find related publications in this database (Keywords): chemotherapy; PEG liposomal doxorubicin; gemcitabine; platinum resistance; ovarian cancer